Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...
The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Key Takeaways The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic ...
Zacks Investment Research on MSN3d
AMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback